NASDAQ:CADL Candel Therapeutics Q3 2025 Earnings Report $7.67 +0.14 (+1.86%) Closing price 04:00 PM EasternExtended Trading$7.58 -0.09 (-1.11%) As of 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Candel Therapeutics EPS ResultsActual EPS-$0.21Consensus EPS -$0.17Beat/MissMissed by -$0.04One Year Ago EPSN/ACandel Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACandel Therapeutics Announcement DetailsQuarterQ3 2025Date11/13/2025TimeBefore Market OpensConference Call DateThursday, November 13, 2025Conference Call Time8:00AM ETUpcoming EarningsCandel Therapeutics' Q1 2026 earnings is estimated for Tuesday, May 12, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, May 14, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings Documents Candel Therapeutics Earnings HeadlinesCandel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the ...May 4 at 12:21 PM | markets.businessinsider.comCandel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual MeetingMay 4 at 8:05 AM | globenewswire.com$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s known for playing his cards “close to the vest”… Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…May 5 at 1:00 AM | Paradigm Press (Ad)Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comCandel Therapeutics teams up with EVERSANA to prep for prostate cancer drug launchApril 29, 2026 | proactiveinvestors.comCandel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate CancerApril 29, 2026 | globenewswire.comSee More Candel Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Candel Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Candel Therapeutics and other key companies, straight to your email. Email Address About Candel TherapeuticsCandel Therapeutics (NASDAQ:CADL) (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs. In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications. The company’s research and development activities are supported by a combination of in-house expertise in viral immunology and collaborations with academic institutions and contract research organizations. Preclinical studies have demonstrated the potential of Candel’s viral platforms to reshape the tumor microenvironment and synergize with checkpoint inhibitors and other immunotherapies. Headquartered in Pittsburgh, Pennsylvania, Candel Therapeutics conducts clinical trials across multiple sites in North America and Europe. The company was founded by scientists with deep expertise in oncolytic virotherapy and has assembled a management team experienced in advancing viral therapies through regulatory interactions. As a public company listed on Nasdaq under the ticker CADL, Candel continues to expand its scientific capabilities and clinical footprint to bring innovative viral immunotherapies to patients worldwide.View Candel Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir Drops After a Blowout Q1—What Investors Should KnowShopify’s Valuation Crisis Creates Opportunity in 2026onsemi Stock Dips After Earnings: Why the Dip Is BuyableTSLA: 3 Reasons the Stock Could Hit $400 in MayNebius Breaks Out to All-Time Highs—Here's What's Driving It.3 Reasons Analysts Love DexComMonolithic Power Systems: AI Stock Beat, Raised and Upgraded Post-Earnings Upcoming Earnings ARM (5/6/2026)AppLovin (5/6/2026)DoorDash (5/6/2026)Fortinet (5/6/2026)Marriott International (5/6/2026)Warner Bros. Discovery (5/6/2026)Apollo Global Management (5/6/2026)Cencora (5/6/2026)Cenovus Energy (5/6/2026)CVS Health (5/6/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
